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ABSTRACT 
In an attempt to identify tumor suppressor genes on chromosome 10 in non-small cell lung 
cancers, we isolated 10 types of splicing variants of the HELLS/ SMARCA6 gene transcripts. 
HELLS/SMARCA6 is a novel member of SNF2 family, which is implicated in cellular 
function like chromatin remodeling. Variant 1 was an alternatively spliced isoform containing 
an insertion of a 44-ntd intronic sequence between exons 3 and 4, giving rise to a premature 
termination of translation. The expression of the variant 1 was detected exclusively in the 
lung cancer specimens (11 of 43 cases, 26%), but was not detected in corresponding normal 
tissues. D10S520 marker in the proximity of the HELLS/SMARCA6 gene showed prevalent 
allelic loss (41%) as compared with flanking markers (25-31%). These results suggest that 
loss of function of HELLS/SMARCA6 by allelic loss and aberrant proteins by tumor-specific 
exon creation may result in epigenetic deregulation, leading the lung cells to malignancy or 
its progression.  
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INTRODUCTION 
Lung cancer is one of the leading causes of cancer-related deaths in the world. Several areas 
of frequent allelic loss have been found in lung cancers (1-4). Recently, by a high-resolution, 
genome-wide search of loss of heterozygosity (LOH), new regions of allelic loss have been 
identified in lung cancers (5, 6). Allelic loss at human chromosome 10q23-24 has been 
frequently observed in a variety of solid tumors containing lung cancer (7-17). The region is 
also known as a breakpoint region frequently detected in human leukemia cells (18). Recently, 
the HELLS/SMARCA6 gene was identified on chromosome 10q24.2. SMARCA genes 
(SWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A 
genes) are members of the SNF2 gene family. The SNF2 family members have helicase and 
ATPase activities, and are implicated in many features of cellular function, including 
chromatin remodeling, recombination, methylation and transcription (19-22). The multiple 
functions of SNF2 family members suggest that these genes may play important roles as 
tumor suppressor genes, similar to such genes as BRM/SMARCA2 (23), BRG1/SMARCA4 (24, 
25), and HLTF/SMARCA3 (26). BRM/SMARCA2 protein inhibited proliferation by binding 
with RB to induce cell cycle arrest (23). Mutations of the BRG1/SMARCA4 gene were 
detected in prostate, breast, pancreas and lung cancer cell lines (24), and it was shown that 
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loss of BRG1/BRM was correlated with poor prognosis of lung cancer (25). The 
HLTF/SMARCA3 gene has been reported to be a tumor suppressor gene candidate and a 
common target for gene silencing in colon cancers (26). HELLS/SMARCA6 was first 
reported as a putative helicase in murine lymphocytes (27). The helicase domains of 
HELLS/SMARCA6 closely resemble those of mammalian RAD54, another member of the 
SNF2 family, whose mutations are associated with tumorigenesis (28, 29). Recently, it has 
been reported that HELLS/SMARCA6 plays an important role in DNA metabolism, cellular 
proliferation, CpG methylation and histone methylation (30-32), and an alternatively spliced 
isoform of this gene has been implicated in leukemogenesis (33). We analyzed expression of 
the HELLS/SMARCA6 gene in primary non-small cell lung cancers (NSCLCs) and found 
tumor-specific exon creation of the HELLS/SMARCA6 gene. Furthermore, we found 
prevalent loss of the HELLS/SMARCA6 locus in NSCLCs. 
 
MATERIAL AND METHODS 
Clinical samples 
Surgically resected tissues from primary lung tumors and corresponding normal tissues were 
obtained from patients with lung tumors at Department of Surgical Oncology and Thoracic 
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Surgery, Okayama University Hospital, after acquisition of written informed consent from all 
patients.  
DNA and RNA extraction 
Genomic DNAs were isolated from tumor and normal tissues by SDS/proteinase K treatment, 
phenol/chloroform extraction, and ethanol precipitation. Total RNAs were isolated from 
rapidly frozen samples by using ISOGEN reagent (Nippon Gene, Tokyo, Japan) according to 
the manufacturer’s instructions. 
Reverse transcription-PCR (RT-PCR) and cDNA sequencing  
Oligo(dT)-primed cDNA was synthesized using the ReverTra Ace kit (Toyobo, Tokyo, Japan) 
according to the manufacturer’s instructions. The whole coding region of the 
HELLS/SMARCA6 cDNA was amplified into 4 overlapping fragments by RT-PCR with 4 
pairs of the following primers: sense 5’-CCG GGT GAG TGT CCA GGC A and antisense 5’-
CCG TCG CAT CAC TCC TCC AG for fragment A (693-ntd, exons 1-8); sense 5’-CCG 
GAA GTG TAA TGG TCA GC and antisense 5’-TCA AGA GCA ACA TCA GAC TTC A for 
fragment B (771-ntd, exons 8-13); sense 5’-GCC AGA TGT ATT TGA TGA CTT GA and 
antisense 5’-CCG TGT TGA AGC TGT GCA TGT for fragment C (788-ntd, exons 12-17); 
and sense 5’-TGG ACA TTT TGA TGG ATT ACT GC and antisense 5’-AAA CCC AAT 
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ACA GGG AAA TCA C for fragment D (701-ntd, exons 17-22). Fragment D was used for 
comparing the expression level of the gene. The gene expression in tumor and paired normal 
samples was compared with expression of the glyceraldehyde phosphate dehydrogenase 
(GAPDH) gene as an internal control. For mutation analysis, PCR products were processed 
with the Big Dye terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, 
USA) and analyzed on an ABI 3100 sequencer (Applied Biosystems).  
Nested PCR analysis for alternative splicing variants  
Each PCR product was cloned into pBluescript and sequenced. In order to define and screen 
the alternative splicing isoforms, nested RT-PCR was performed using the following primers: 
sense primer designed in exon 3 (5’-GAG TCG ACA GAA ATT CGG TAC C) and antisense 
primer in exon 5 (5’-CTG GCT TCT CTT CAC TTG CAT C) for a 44-ntd insertion between 
exons 3 and 4 (variant 1). Primers used for specific detection of other variants are available 
on request. The amplified products were separated by 2% agarose gel electrophoresis to 
identify each variant. 
Loss of heterozygosity (LOH) analysis 
To evaluate allelic loss at chromosome 10q23-24, highly polymorphic microsatellite markers 
D10S520 (about 60 kbp telomeric to the Hells), D10S1680 (about 700 kbp centromeric) and 
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10q23MS3 (about 600 kbp telomeric) were used. PCR primers for D10S520 and D10S1680 
are available from the internet genome database (http://gdbwww.gdb.org). For the 10q23MS3 
marker (GenBank accession number AB118108), forward primer 5’-CAA GGC ACT AAG 
CTC TGT ATT C and reverse primer 5’-TAT CCT GAC TGC CTG TGG TAG were used. 
The forward primers were labeled with iodoacetamidofluorescein at the 5’-end and used for 
PCR. The PCR products were analyzed on a PRISM 3100 Analyzer with GeneScan Analysis 
software version 3.7 (Applied Biosystems). LOH was scored if one of heterozygous alleles 
showed at least 70% reduced intensity in tumor DNA as compared with the corresponding 
normal DNA. 
Immunohistochemistory  
Primary lung tumors fixed in 4% paraformaldehyde were embedded in paraffin and cut 5 μm 
increments. They were stained with hematoxylin and eosin, and immunostained with goat 
polyclonal antibody against carboxyl terminus of Lymphoid-Specific Helicase, Lsh/Hells (M-
15, x100; Santa Cruz Biotechnology, Santa Cruz, CA) using avidin-biotin-horseradish 
peroxidase complex method (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) 
with diaminobenzidine.  
Statistical analysis 
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 For analysis of relationship between clinical data and SMARCA6 variants, Fisher's exact test 
and Spearman’s correlation coefficient test were used. 
 
RESULTS 
Expression of the Hells/SMARCA6 gene in NSCLCs  
In order to identify the tumor suppressor genes for NSCLCs on chromosome 10q23-24, the 
expression level of the HELLS/SMARCA6 gene was analyzed by semi-quantitative RT-PCR 
with mRNA from the 34 tumor tissue samples and corresponding normal tissue samples. 
Decreased expression of the HELLS/SMARCA6 gene was detected in 9 of the 34 tumor 
tissues (26%) as compared with those of the matched normal tissues (data not shown). In 18 
of the 34 tumor tissues (53%), a similar level of the gene expression was observed in tumors 
and matched normal tissues. Increased expression of the HELLS/SMARCA6 gene was found 
in 7 of 34 (21%) tumor tissues.  
Mutation analysis of the HELLS/SMARCA6 gene 
We amplified the HELLS/SMARCA6 transcripts by RT-PCR with four pairs of primers to 
produce four fragments A, B, C and D, and sequenced these to find mutations in NSCLCs. No 
mutations were detected, but we found a single nucleotide polymorphism (SNP) at codon 77 
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(ATA or ATC) that yielded no amino acid change (data not shown).  
Identification of 10 splicing variants of the HELLS/SMARCA6 gene  
As RT-PCR and sequencing analyses of the HELLS/SMARCA6 gene suggested the existence 
of some splice variants, each fragment of the RT-PCR products from some of the tumor 
samples was cloned into plasmids and sequenced. We found ten alternatively spliced variants 
(GenBank accession numbers AB102716-AB102723, AB113248 and AB113249). Variant 1 
showed a 44-ntd insertion between exons 3 and 4, which was detected in 11 of 42 plasmid 
clones of fragment A (26.2%). Sequencing analysis revealed that this 44-ntd insertion was 
derived from intron 3 (Figure 1). No mutation was detected in the exon-intron boundaries and 
intron 3 (data not shown). Variant 2, which shows a splicing out of exon 6, was detected in 9 
of 42 clones (21.4%) (Figure 2). A partial deletion of exon 10 (variant 3) was detected in 3 of 
38 clones of fragment B (7.8%). Variant 4, which shows a splicing out of exons 10 (3’-half), 
11 and 12, was detected in 4 of 38 clones (10.5%). A skipping of exon 11 (variant 5) was 
detected in 1 of 38 clones (2.6%). A deletion of both exons 11 and 12 (variant 6) was detected 
in 8 of 38 clones (15.8%). Variant 7, which shows a deletion of the 3’-half of exon 10 and a 
15-ntd insertion between exons 10 and 11, was detected in 1 of 38 clones (2.6%). A 138-ntd 
insertion between exons 12 and 13 (variant 8) was detected in 1 of 38 clones (2.6%). Variant 
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9, which has a 75-ntd deletion in exon 18, was detected in 8 of 42 clones (19%) of fragment 
D. Variant 10, which does not splice intron 20 out, was detected in 3 of 42 clones (7.1%). 
Variants 1, 2, 5, 7, 9 and 10 cause frameshifts, and result in premature termination of 
translation, while variants 3, 4, 6 and 8 retain the open reading frame (Figures 1 and 2).  
Detection of splicing variants by nested PCR analysis 
In order to analyze the expression of these splicing variants in NSCLCs and corresponding 
normal tissues, we performed RT-PCR analysis specific for each variant. Variant 1 was 
detected in 11 of 43 (26%) NSCLC tissues, however, interestingly, we could not find this 
variant in any of the 43 normal lung tissues we examined. Representative cases are shown in 
Figure 1D. We found a cryptic blanching point which has a conserved flanking sequence 
(ccctgac) identical to the consensus sequence, and a polypyrimidine tract located in the intron 
just before the 44-ntd sequence. No mutation was detected in the exon-intron boundary and 
intron 3. Furthermore, we analyzed expression level of the hnRNP A2 and B1 genes in 
NSCLC tissues by RT-PCR, as it has been reported on association of expression ratio of the 
hnRNP A2/B1 genes with RNA splicing error (34, 35) and association of the elevated hnRNP 
B1 mRNA level with human lung cancers (36). However, the expression of hnRNP A2 and B1 
was detected with similar level in tumor samples with and without variant 1, and no 
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remarkable differences of expression level were detected between tumor and normal tissues 
(data not shown). We examined the relationship between the variant 1 expression and clinical 
data (Table I). However, there was no significant correlation between the expression and the 
clinical data. The variant 1 was also found in 6 of 8 lung cancer cell lines (data not shown). 
Other variants (2 to 10) were detected in both tumor and normal tissues. Detection frequency 
of the alternative variants and representative cases are shown in Figures 2 and 3, respectively.  
Loss of heterozygosity (LOH) around the HELLS/SMARCA6 gene 
We analyzed allelic loss with 3 microsatellite markers at chromosome 10q23-24 in 37 
primary NSCLCs along with corresponding normal lung tissues (Figure 4). Microsatellite 
marker D10S520, which is located near the HELLS/SMARCA6 gene, showed highly-frequent 
LOH in 11 of 27 (41%) informative cases. However, LOH with the flanking markers at a 
distance of about 700 kbp from D10S520 was shown in only 6 of 24 (25%) with centromeric 
marker D10S1680, and in only 9 of 29 (31%) with telomeric marker 10q23MS3. In particular, 
cases 117 and 119 showed LOH only at D10S520, and cases 195, 106, 134 and 140 exhibited 
common LOH at D10S520, suggesting the existence of tumor suppressor genes in this region. 
Of 11 tumors that expressed the variant 1 of the HELLS/SMARCA6, 7 showed LOH (64%), 3 
were non-informative, and only 1 sample showed retention of the D10S520 locus. There was 
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no significant correlation between the expression level of the HELLS/SMARCA6 gene and 
allelic loss at D10S520. 
Immunohistochemical analysis of HELLS/SMARCA6 expression 
We examined the expression of HELLS/SMARCA6 protein in some specimens of NSCLCs 
with commercial antibody against the carboxyl terminal region (Figure 5). In 5 cases of the 
tumor in which the variant 1 transcript was detected, the protein expression was almost same 
level as that of 5 tumor cases in which the variant 1 transcript was not detected. We found no 
difference of the immunostaining signal in the tumor and corresponding normal lung tissues. 
DISCUSSION 
In this study, we identified 10 splicing variants of the HELLS/SMARCA6 gene in NSCLCs. It 
is remarkable that variant 1, with a 44-ntd insertion between exons 3 and 4, was detected 
exclusively in tumor samples (26%, 11/43 cases) but not in corresponding normal tissues. 
There were no registered expressed sequence tags (EST) harboring the 44-ntd sequence in the 
NCBI hEST database, indicating that the 44-ntd is a truly intronic sequence. A cryptic 
blanching point and polypyrimidine tract, which we detected in intron upstream of the 44-ntd 
insertion, might be used for formation of splicing lariat structure upon the alternative splicing. 
Previous results, that this protein is required for normal CpG methylation and is crucial for 
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formation of normal histone methylation (31, 32), and our results, that showed the frequent 
loss of this locus, suggest that this gene product may normally function as a tumor suppressor. 
As the variant 1 mRNA is expected to produce a prematurely-terminated polypeptide of 97 
amino acid residues, the peptide may function in a dominant-negative manner against the 
normal HELLS/SMARCA6 protein (838 aa). It may be supported by the recent report that the 
nuclear localization domain of this protein is located between at least amino acids 31 and 176 
(37). It will be desired to perform transfection experiments with the variant 1 and/or full-
length HELLS/SMARCA6 cDNA expression vectors, and the protein expression analysis with 
customized HELLS/SMARCA6 antibodies, in order to clarify these unsolved issues. 
Confirmation of the variant 1 protein by western blotting was not performed, because the 
commercial antibody was made against the carboxyl terminal region of HELLS/SMARCA6. 
    The hnRNP A2 and B1 genes have been reported to be involved in RNA splicing, 
transport (34, 35), and are associated with human lung cancers (36). Therefore, we analyzed 
the ratio of hnRNP A2/B1 gene expression in NSCLCs. However, the expression was at 
almost the same level in most samples, suggesting that the expression of the hnRNP A2 and 
B1 genes is not correlated with the production of variant 1. However, we can not exclude the 
possibility that the up-regulation of hnRNPA2/B1 occurs at the post-transcriptional level (38). 
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     It has been reported that the alternative isoform with 75-ntd deletion in exon18 (variant 
9) was detected in 57% of acute myelogenous leukemias and 37% of acute lymphoblastic 
leukemias, but was not in ovarian caricinomas and normal tissues containing thymus, bone 
marrow, peripheral blood mononuclear cells, testis, ovary and lymph node (33). In the present 
study, the variant 9 was detected in 7 of 37 (19%) primary lung tumors and in 5 of 37 (14%) 
normal lung tissues. These results suggest that the normal lung tissues in our cases may be 
already affected by initiation of tumorigenesis like field cancerization, or that the variant 9 
may be expressed in some normal tissues containing lung. Defining the expression pattern in 
other tissues will be also required for further analyses. 
     Our results reveal an association of the splicing variant 1 of the HELLS/SMARCA6 
gene with a considerable subset of NSCLC by a novel “exon-creation” mechanism for gene 
inactivation. To our knowledge, there are few descriptions of such a mechanism relevant to 
tumorigenesis with high frequency, though it has been reported that cryptic exons are 
involved in the activation of the EWS-FLI1 chimeric gene in Ewing sarcomas (39). Although 
it is possible that progression of lung cancer leads to a disturbance of splicing machinery and 
produces alternatively spliced variants in a tumor-specific manner, the tumor-specific variant 
1 could be useful as a tumor marker for NSCLCs. Further study, including a functional 
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analysis, will be required to uncover the role of this variant in the tumorigenesis of the lung 
epithelium.  
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TABLE I - RELATIONSHIP BETWEEN VARIANT 1 AND CLINICAL DATA 
  No.  No. of  No. of 
of cases variant 1 (+) (%) variant 1(-) (%) p - value 
Age     
     < 65 year 22 3 (14)  19 (86)  
     65 year< 28 10 (36)  18 (64)  p = 0.11 
Gender     
     Male  41 10 (24)  31 (76)  
     Female 9 3 (33)  6 (67)  p = 0.68 
Smoking history      
     Non-smokers 9 3 (33)  6 (67)  
     < 400 1 0 (0)  1 (100)  
     400<  37 9 (24)  32 (76)  p = 0.56 
TNM classification     
     I  29 8 (28)  21 (72)  
     II  10 3 (30)  7 (70)  
     III  10 1 (10)  9 (90)  
     IV  1 1 (100)  0 (0)  p = 0.74 
Tumor size     
     T1  21 5 (24)  16 (76)  
     T2  17 5 (29)  12 (71)  
     T3  10 2 (20)  8 (80)  
     T4  2 1 (50)  1 (50)  p = 0.81 
Lymph node metastasis     
     Positive 16 3 (19)  13 (81)  
     Negative 34 10 (29)  24 (71)  p = 0.51 
Histology     
     AD  30 9 (30)  21 (70)  
     SQ  20 4 (20)  16 (80)  p = 0.52 
Differentiation      
     Well  13 2 (15)  11 (85)  
     Moderate 20 7 (35)  14 (65)  
     Poor  17 4 (24)  13 (76)  p = 0.71 
  
Tumor staging was determined according to International Union Against Cancer (UICC) TNM 
classification of malignant tumors. AD, adeno carcinoma; SQ, squamous cell carcinoma.  
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 FIGURE LEGENDS 
Figure 1. Splicing variant of the HELLS/SMARCA6 gene with a 44-ntd insertion (variant 1). 
(A) Sequencing result of variant 1. (B) Schematic illustration of variant 1. Arrows show the 
alternative splicing pattern. An asterisk shows a premature termination site. (C) Nucleotide 
and amino acid sequences of variant 1. Upper case letters show exons, and lower case letters 
show splicing junctions in introns. Amino acids are shown according to triplet nucleotides 
with underlining. (D) Nested PCR products for variant 1. Numbers at top show patient 
number. M, molecular weight marker; T, tumor sample; N, normal sample. Only tumor 
samples exhibit PCR products of variant 1 with a 44-ntd insertion (Var 1, 238-ntd) in addition 
to the normal transcript (Norm, 194-ntd). 
 
Figure 2. Schematic illustration of 9 splicing variants of the HELLS/SMARCA6 gene. 
Arrows show the alternative splicing pattern. Shaded boxes show the region which was 
spliced into the mRNAs, and open boxes show the exon which was spliced out. Asterisks 
show the premature termination site. PMT stands for premature termination. Frequency of 
each splicing variant detected in tumor (T) and normal (N) samples is shown at right. E, 
exon; Int, intron; ins, insertion. 
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Figure 3. Representative cases of splicing variants of the HELLS/SMARCA6 gene. (A) Nested 
PCR products for variant 2. Numbers at top show patient number. M, molecular weight 
marker; T, tumor sample; N, normal sample. (B) Nested PCR products for variants 3-6. PCR 
products with 105T or 53T sample show variants 3-6 and normal transcript while the variant 
5 is faint in 105T. PCR products with the 105N sample shows variants 3, 4 and normal 
transcript. 107T shows variants 4, 5, 6 and a trace amount of normal transcript, while 107N 
shows variants 3, 6 and normal transcript. (C) Nested PCR for variant 9. PCR products with 
113N or 125T samples show normal transcript (285-ntd) and variant 9 (210-ntd), while those 
of 113T, 125N, 136T and 136N samples show normal transcript. (D) Nested PCR for variant 
10. PCR products with primers designed on exons 20 and 22 show normal transcript (199-
ntd) and variant 10 (277-ntd) which has intron 20 (78-ntd) but not intron 21.  
 
Figure 4. LOH analysis around the HELLS/SMARCA6 gene on chromosome 10q.  
Microsatellite marker D10S520 which is located near the HELLS/SMARCA6 gene, the 
centromeric marker D10S1680, and the telomeric marker 10q23MS3 were used. Black box, 
LOH; open box, retention; shaded box, not informative. 
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Figure 5. HELLS/SMARCA6 expression in lung cancer and normal tissues.  
The specimens of the patients with lung tumor in which the variant 1 was detected (A, B an 
C) and with lung tumor in which the variant 1 was not detected (D, E and F) were 
immunostained using the antibody against HELLS/SMARCA6 (B, C, E and F) and 
counterstained with hematoxylin and eosin (A and D). A, B, D and E, lung tumor; C and F, 
corresponding normal lung tissue. 
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